Chugai Pharmaceutical Co., Ltd.
4519
Kedudukan dalam Saham
#350
Chugai Pharmaceutical Co., Ltd. is a prominent global pharmaceutical company,... Chugai Pharmaceutical Co., Ltd. is a prominent global pharmaceutical company, operating subsidiaries involved in the full lifecycle of drug development, from research and manufacturing to sales, import, and export, serving both Japanese and international markets. Its commercialized product portfolio spans several key therapeutic areas. These include a robust oncology offering with leading treatments like Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda. Additionally, it provides medications for bone health (e.g., Actemra, Edirol, Bonviva), renal conditions (such as Mircera and Oxarol), and neurological or other diverse ailments (including Hemlibra, CellCept, and Enspryng). Beyond its existing offerings, the company maintains an active research and development pipeline. This pipeline features multiple promising candidates targeting oncology, orthopedic and joint disorders, autoimmune diseases, kidney-related conditions, and various neurological or other health issues. Strategic partnerships are central to Chugai's operations, most notably a significant alliance with the Roche Group. The company also fosters collaborative research initiatives with academic institutions. Established in 1925, Chugai's headquarters are located in Tokyo, Japan, and it operates as a key subsidiary of Roche Holding Ltd.
Harga Saham
$41.60
Modal Pasaran
$68.46B
Perubahan (1 hari)
0.94%
Perubahan (1 tahun)
-12.56%
Negara
JP
Perdagangan Chugai Pharmaceutical Co., Ltd. (4519)
Kategori
Healthcare
Hasil untuk Chugai Pharmaceutical Co., Ltd. (4519)
Hasil pada Oct 2026 TTM: 0
Menurut laporan kewangan terkini daripada Chugai Pharmaceutical Co., Ltd., hasil semasa syarikat (TTM) ialah 0. Pada tahun 2026, syarikat memperoleh hasil sebanyak 0 sama dengan hasil pada tahun 2026 iaitu 0. Hasil ialah jumlah pendapatan keseluruhan yang dijana oleh syarikat daripada jualan barangan atau perkhidmatan. Tidak seperti keuntungan, tiada perbelanjaan ditolak.
Sejarah hasil bagi Chugai Pharmaceutical Co., Ltd. dari 2003 hingga 2026
Hasil pada akhir setiap tahun
| Tahun | Hasil | Ubah |
|---|---|---|
| 2025 | $8.02B | 7.55% |
| 2024 | $7.46B | -5.39% |
| 2023 | $7.88B | -17.99% |
| 2022 | $9.61B | 10.64% |
| 2021 | $8.69B | 13.94% |
| 2020 | $7.62B | 20.73% |
| 2019 | $6.31B | 19.38% |
| 2018 | $5.29B | 11.54% |
| 2017 | $4.74B | 12.75% |
| 2016 | $4.21B | 1.47% |
| 2015 | $4.14B | 7.63% |
| 2014 | $3.85B | -4.30% |
| 2013 | $4.02B | -9.99% |
| 2012 | $4.47B | -7.65% |
| 2011 | $4.84B | 3.55% |
| 2010 | $4.67B | 1.15% |
| 2009 | $4.62B | 28.26% |
| 2008 | $3.60B | 16.82% |
| 2007 | $3.08B | 12.50% |
| 2006 | $2.74B | -1.26% |
| 2005 | $2.78B | -3.34% |
| 2004 | $2.87B | 32.23% |
| 2003 | $2.17B | 0.00% |
Hasil untuk syarikat atau pesaing serupa
| Syarikat | Hasil | Perbezaan Hasil | Negara |
|---|---|---|---|
| $79.67B | - |
US
|
|
| $99.34B | - |
US
|
|
| $64.39B | - |
US
|
|
| $66.40B | - |
US
|
|
| $77.52B | - |
CH
|
